Leukemia

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
Leukemia - Tập 18 Số 4 - Trang 676-684 - 2004
Chihaya Imai, Keichiro Mihara, Martin Andreánsky, I. Nicholson, C‐H Pui, Terrence L. Geiger, Dario Campana
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
Leukemia - Tập 30 Số 2 - Trang 492-500 - 2016
Daniel Sommermeyer, Michael Hudecek, Paula L. Kosasih, Tea Gogishvili, David G. Maloney, Cameron J. Turtle, Stanley R. Riddell
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
Leukemia - Tập 24 Số 6 - Trang 1160-1170 - 2010
Valentina Hoyos, Barbara Savoldo, Concetta Quintarelli, Aruna Mahendravada, Ming Zhang, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, Malcolm K. Brenner, Gianpietro Dotti
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
Leukemia - Tập 28 Số 4 - Trang 917-927 - 2014
Jianjun Chu, Youcai Deng, D.M. Benson, Shun He, Tiffany Hughes, Jian Zhang, Yong Peng, Hongyi Mao, Ling Yi, Kalpana Ghoshal, Xiaoming He, Steven M. Devine, Xiaoliu Zhang, Michael A. Caligiuri, Craig C. Hofmeister, Jianhua Yu
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts
Leukemia - Tập 27 Số 8 - Trang 1677-1687 - 2013
Silvia L. Locatelli, Arianna Giacomini, Anna Guidetti, Loredana Cleris, Roberta Mortarini, Andrea Anichini, Alessandro M. Gianni, Carmelo Carlo‐Stella
Nuclear transcription factor-κB as a target for cancer drug development
Leukemia - Tập 16 Số 6 - Trang 1053-1068 - 2002
Amit Garg, BB Aggarwal
Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed–Sternberg cells
Leukemia - Tập 26 Số 4 - Trang 806-813 - 2012
Rolf Schwarzer, Bernd Dörken, Franziska Jundt
Lymphopain, a cytotoxic T and natural killer cell-associated cysteine proteinase
Leukemia - Tập 12 Số 11 - Trang 1771-1781 - 1998
Jason Brown, E Matutes, Alison M. Singleton, Cathy J. Price, H. V. Molgaard, David J. Buttle, Tariq Enver
High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia
Leukemia - Tập 11 Số 2 - Trang 185-189 - 1997
James A. Whitlock, RJ Wells, JD Hord, RL Janco, JP Greer, JC Gay, JR Edwards, TL McCurley, JN Lukens
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
Leukemia - Tập 30 Số 8 - Trang 1701-1707 - 2016
Claire Harrison, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, Heinz Gisslinger, Laurent Knoops, Francisco Cervantes, Mark M. Jones, Kang Sun, Mari McQuitty, Viktoriya Stalbovskaya, Prashanth Gopalakrishna, Tiziano Barbui
Abstract Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies. COMFORT-II was a randomized (2:1), open-label phase 3 study in patients with myelofibrosis; patients randomized to BAT could crossover to ruxolitinib upon protocol-defined disease progression or after the primary end point, confounding long-term comparisons. At week 48, 28% (41/146) of patients randomized to ruxolitinib achieved ⩾35% decrease in spleen volume (primary end point) compared with no patients on BAT (P<0.001). Among the 78 patients (53.4%) in the ruxolitinib arm who achieved ⩾35% reductions in spleen volume at any time, the probability of maintaining response was 0.48 (95% confidence interval (CI), 0.35–0.60) at 5 years (median, 3.2 years). Median overall survival was not reached in the ruxolitinib arm and was 4.1 years in the BAT arm. There was a 33% reduction in risk of death with ruxolitinib compared with BAT by intent-to-treat analysis (hazard ratio (HR)=0.67; 95% CI, 0.44–1.02; P=0.06); the crossover-corrected HR was 0.44 (95% CI, 0.18–1.04; P=0.06). There was no unexpected increased incidence of adverse events with longer exposure. This final analysis showed that spleen volume reductions with ruxolitinib were maintained with continued therapy and may be associated with survival benefits.
Tổng số: 165   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 17